Medical Dialogues6d
Phase 3 study comparing Yesintek with Stelara in adult patients with chronic plaque psoriasis shows positive results: Biocon Biologics
Bengaluru: BioconBiologics Ltd., a fully integrated global biosimilars company and subsidiary of Biocon Ltd. has announced ...
Le Lézard7d
Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintektm Biosimilar to Ustekinumab for Chronic Plaque Psoriasis
Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced the successful results of a pivotal Phase 3, ...
Morningstar7d
Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis
BRIDGEWATER, N.J., and BENGALURU, India, March 7, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code ...
Seeking Alpha15d
Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2024 Earnings Call Transcript
Greetings, and welcome to the Catalyst Pharmaceuticals Fourth Quarter and Full-Year 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and ...
Investing15d
Earnings call transcript: Catalyst Pharmaceuticals Q4 2024 beats expectations
Catalyst Pharmaceuticals’ Q4 2024 EPS of $0.70 beat forecasts by over 118%. Revenue for the quarter reached $141.8 million, a 28.3% year-over-year increase. The stock price rose by 11.08% in ...
Investing15d
Earnings call transcript: Catalyst Pharmaceuticals Q4 2024 beats expectations
Catalyst Pharmaceuticals’ Q4 2024 EPS of $0.70 beat forecasts by over 118%. Revenue for the quarter reached $141.8 million, a 28.3% year-over-year increase. The stock price rose by 11.08% in ...
Indiatimes27d
Dr Loganathan Murugan
As the Kashi Tamil Sangamam 2025 commences today, it is yet another testimony to India’s unity in diversity. This unique cultural confluence, being held from February 15-24, 2025, brings ...